We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Review · February 16, 2021

Prevalence and Survival of RCC Among Patients Eligible for Adjuvant Checkpoint Inhibitor Trials

Clinical Genitourinary Cancer


Additional Info

Clinical Genitourinary Cancer
Prevalence, Disease-Free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials
Clin Genitourin Cancer 2021 Jan 07;[EPub Ahead of Print], L Marconi, M Sun, C Beisland, T Klatte, B Ljungberg, GD Stewart, S Dabestani, TK Choueiri, A Bex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading